Abstract
Evaluation of: Martinez Del Pero M, Chaudhry A, Jones RB et al.: B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study. Clin. Otolaryngol. 34(4), 328–335 (2009). In this study, Martinez del Pero et al. examined the effects of rituximab therapy in patients with head and neck manifestations of Wegener’s granulomatosis that were refractory to treatment with standard therapies. Rituximab was overall well tolerated and effective. At 6 months, rituximab induced disease remission in 88% of patients (62% complete and 26% partial remission). All patients who did not respond to the first course achieved remission after a second course of rituximab. Four out of five patients with ocular masses showed a good response to rituximab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
